Patient Considerations Following Treatment With Radium-223
Neal D. Shore, MD, FACS, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.
Clinical Pearls
Radium-223 gets into bone lesions in a matter of minutes, Shore says. Radium-223 is not metabolized by a patient's kidneys or liver, it is simply decayed into fecal matter. A patient is at no real risk following infusion, but should avoid contact with fecal matter.
- Radium-223 gets into bone lesions in a matter of minutes
- The agent is not metabolized by a patient's kidneys or liver
- There is no risk post-infusion, other than avoiding fecal matter
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
